Shire Sues Anchen Over Generic Intuniv

Law360, New York (June 3, 2010, 1:17 PM EDT) -- Shire PLC has filed suit against Anchen Pharmaceuticals Inc., continuing its crusade to block generic versions of attention deficit hyperactivity disorder treatment Intuniv from entering the market prior to the expiration of patents for the drug's active ingredient.

Shire's Shire LLC subsidiary lodged the suit Wednesday in the U.S. District Court for the District of Delaware, accusing Anchen of infringing three patents covering guanfacine hydrochloride extended release tablets, which are sold under the Intuniv brand name.

The suit stems from an abbreviated new drug application Anchen...
To view the full article, register now.